Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Flexible braille indicia signage and methods are provided. Preferably, the flexible braille indicia signage takes the form of braille directional identifiers for use on railings or the like. In one example, the braille indicia signage is made by providing a flexible substrate and printing a first layer of ink on a first side of the flexible substrate in a pattern defining desired braille indicia. Multiple layers of ink are then printed in registration with the pattern atop of the first layer of ink such that the desired braille indicia has a height of at least 0.6 mm (0.79 mm for braille directional identifiers) relative to the first side of the substrate. A sealing layer of ink is then printed atop the substrate and multiple layers of ink. The result is a braille sign with braille indicia that does not separate from the substrate on a condition that a portion of the substrate bearing the braille indicia is flexed in an arc of a 10 mm, i.e.

Abstract: Embodiments of the present invention include a computer program product, a computer system, and a computer-implemented method for generating a data model that machine learns from social media postings to determine whether social media postings will gain traction.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed for watermark outage detection. Example methods include evaluating an onset time and duration of a detected watermark outage based on a model of expected watermark outages to determine whether the detected watermark outage corresponds to at least one of the expected watermark outages represented in the model. Example methods further include generating an alert in response to determining the detected watermark outage does not correspond to at least one of the expected watermark outages included in the model, and suppressing the alert in response to determining the detected watermark outage corresponds to the at least one of the expected watermark outages represented in the model.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed for watermark outage detection. Example methods include evaluating an onset time and duration of a detected watermark outage based on a model of expected watermark outages to determine whether the detected watermark outage corresponds to at least one of the expected watermark outages represented in the model. Example methods further include generating an alert in response to determining the detected watermark outage does not correspond to at least one of the expected watermark outages included in the model, and suppressing the alert in response to determining the detected watermark outage corresponds to the at least one of the expected watermark outages represented in the model.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Embodiments of the present invention include a computer program product, a computer system, and a computer-implemented method for generating a data model that machine learns from social media postings to determine whether social media postings will gain traction.

Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed for watermark outage detection. Example methods include evaluating an onset time and duration of a detected watermark outage based on a model of expected watermark outages to determine whether the detected watermark outage corresponds to at least one of the expected watermark outages represented in the model. Example methods further include generating an alert in response to determining the detected watermark outage does not correspond to at least one of the expected watermark outages included in the model, and suppressing the alert in response to determining the detected watermark outage corresponds to the at least one of the expected watermark outages represented in the model.

Abstract: Flexible braille indicia signage and methods are provided. Preferably, the flexible braille indicia signage takes the form of braille directional identifiers for use on railings or the like. In one example, the braille indicia signage is made by providing a flexible substrate and printing a first layer of ink on a first side of the flexible substrate in a pattern defining desired braille indicia. Multiple layers of ink are then printed in registration with the pattern atop of the first layer of ink such that the desired braille indicia has a height of at least 0.6 mm (0.79 mm for braille directional identifiers) relative to the first side of the substrate. A sealing layer of ink is then printed atop the substrate and multiple layers of ink. The result is a braille sign with braille indicia that does not separate from the substrate on a condition that a portion of the substrate bearing the braille indicia is flexed in an arc of a 10 mm, i.e.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed for watermark outage detection. Example methods include evaluating an onset time and duration of a detected watermark outage based on a model of expected watermark outages to determine whether the detected watermark outage corresponds to at least one of the expected watermark outages represented in the model. Example methods further include generating an alert in response to determining the detected watermark outage does not correspond to at least one of the expected watermark outages included in the model, and suppressing the alert in response to determining the detected watermark outage corresponds to the at least one of the expected watermark outages represented in the model.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.